Merck Launches 'Let's Talk Trials' Initiative to Address Persistent Gaps in Clinical Trial Representation

Clinical trials remain the cornerstone of evidence-based medicine, yet the populations most impacted by disease continue to be underrepresented in the research that shapes their treatment options. In oncology, only 4%–6% of clinical trial participants are Black and 3%–6% are Hispanic, even though these communities shoulder a significantly larger share of the cancer burden. More broadly, while over 40% of the U.S. population identifies as part of a racial or ethnic minority group, only about 24% of clinical trial participants come from these communities.

To address these persistent disparities, Merck (搜索)搜索该词条 has launched Let's Talk Trials, a new initiative designed to spark earlier conversations about clinical research, particularly within historically underrepresented communities. The program, led by Adrelia Allen, executive director of clinical trial patient representation at Merck Research Laboratories, moves beyond recruitment metrics to focus on education, trust-building, and community-based outreach.

"Conversations about clinical research aren't consistently happening between healthcare providers and patients," Allen noted. "Many individuals simply aren't introduced to clinical research early enough to fully understand what participation involves or whether it may be an option for them."

The Awareness Gap

A national poll from the Patient Advocate Foundation underscores the disconnect: 75% of adults living with chronic illness express interest in learning more about clinical trials but report they do not have the information needed to apply and participate. Research suggests these awareness and information gaps may be even greater among historically underrepresented populations.

Access barriers compound the problem. Practical considerations such as transportation, care partner responsibilities, work schedules, and proximity to clinical trial sites all influence whether individuals can realistically consider participation. For others, perceptions of clinical research are shaped by previous healthcare experiences, uncertainty about the process, or questions about whether participation will feel relevant, respectful, and inclusive.

"Improving representation requires addressing these factors together and creating more opportunities for people to learn about clinical research earlier — before they're ever asked to consider participation," Allen explained.

A Proactive Approach to Education

Let's Talk Trials is grounded in the belief that when people have access to clear, culturally relevant information, they are better positioned to make informed decisions about their healthcare. Rather than focusing solely on participation, the initiative seeks to increase understanding of clinical research earlier through education, trusted partnerships, and community-based outreach.

The program offers a suite of educational resources, including a fact sheet addressing common misconceptions about clinical trials, a brochure explaining clinical trials and the importance of representation, and an FAQ covering topics such as eligibility, participant rights, and how to initiate conversations about the clinical research process. These materials have been translated into Spanish and are shared at events serving Spanish-speaking audiences.

Community-based outreach forms another core component. Through collaborations with advocacy organizations and community groups, Let's Talk Trials creates opportunities for individuals to engage with information about clinical research in environments where they already seek health information and support. The initiative has participated in events such as the Dia de la Mujer Latina Health Fiesta and the Alpha Kappa Alpha Sorority, Incorporated North Atlantic Regional Conference.

Partnerships and Practical Support

Merck (搜索)搜索该词条 has partnered with organizations including Acclinate (搜索)搜索该词条 to engage historically underrepresented communities through educational outreach and resource distribution. A partnership with Suvoda (搜索)搜索该词条 (formerly Greenphire) helps address practical barriers such as transportation support for participants traveling to clinical trial sites.

Importantly, these conversations are designed to be two-way. "They're not only intended to share information but also to create opportunities for listening and learning," Allen said. Through conversations with patients, care partners, advocacy organizations, and community leaders, Merck (搜索)搜索该词条 gains insight into the questions, concerns, and experiences that shape how people view clinical research — insights that help inform future engagement efforts.

A Coordinated Ecosystem Effort

Allen emphasized that improving representation requires a coordinated effort from the entire clinical research ecosystem. This includes more intentional approaches to site selection, incorporating patient and community perspectives earlier in the clinical trial design and planning process, and addressing practical barriers that may influence participation.

"Efforts like Let's Talk Trials are part of our broader, long-standing commitment to improving representation in clinical research," Allen said. "The initiative reflects a holistic approach that connects community engagement, trust-building, and real-world considerations across the clinical research process, rather than addressing these elements in isolation."

By creating opportunities for individuals to explore clinical research with greater understanding and confidence, the initiative aims to help build a future where participation becomes a more accessible consideration rather than an unfamiliar concept introduced at a critical moment in a patient's healthcare journey.